Foundry Healthcare DelEqu Factor ETF
ETF Foundry Research (hypothetical) · rebalanced monthly
Every other metric on this page is the long-shortstrategy, which needs a short book. This fund is the long leg alone, so these are the figures for what it actually holds. The bottom-bucket number is that basket’s own return — not short P&L.
Hypothetical growth of $1 — long-short backtest
Gross of the placeholder expense ratio and trading costs · not investor results
Holdings
Every constituent of the long leg — sort, search or filter by sector
| Ticker | Company | Sector | Market cap | Weight |
|---|---|---|---|---|
1RVMD | REVOLUTION MEDICINES INC | Healthcare | $39.58B | 15.77% |
2MRNA | MODERNA INC | Healthcare | $24.53B | 9.78% |
3UTHR | UNITED THERAPEUTICS CORP | Healthcare | $22.74B | 9.06% |
4BBIO | BRIDGEBIO PHARMA INC | Healthcare | $15.94B | 6.35% |
5MDGL | MADRIGAL PHARMACEUTICALS INC | Healthcare | $12.76B | 5.09% |
6CYTK | CYTOKINETICS INC | Healthcare | $9.98B | 3.98% |
7HALO | HALOZYME THERAPEUTICS INC | Healthcare | $9.23B | 3.68% |
8IBRX | IMMUNITYBIO INC | Healthcare | $8.04B | 3.21% |
9CHE | CHEMED CORP | Healthcare | $6.77B | 2.70% |
10TFX | TELEFLEX INC | Healthcare | $5.96B | 2.38% |
11CELC | CELCUITY INC | Healthcare | $4.31B | 1.72% |
12VKTX | VIKING THERAPEUTICS INC | Healthcare | $4.31B | 1.72% |
13DOCS | DOXIMITY INC | Healthcare | $3.94B | 1.57% |
14RLAY | RELAY THERAPEUTICS INC | Healthcare | $3.81B | 1.52% |
15DNLI | DENALI THERAPEUTICS INC | Healthcare | $3.70B | 1.47% |
16ACHC | ACADIA HEALTHCARE COMPANY INC | Healthcare | $3.17B | 1.26% |
17RARE | ULTRAGENYX PHARMACEUTICAL INC | Healthcare | $2.88B | 1.15% |
18XRAY | DENTSPLY SIRONA INC | Healthcare | $2.81B | 1.12% |
19CLDX | CELLDEX THERAPEUTICS INC | Healthcare | $2.77B | 1.11% |
20BCRX | BIOCRYST PHARMACEUTICALS INC | Healthcare | $2.36B | 0.94% |
21AGIO | AGIOS PHARMACEUTICALS INC | Healthcare | $2.36B | 0.94% |
22BHVN | BIOHAVEN LTD | Healthcare | $2.32B | 0.93% |
23SION | SIONNA THERAPEUTICS INC | Healthcare | $2.23B | 0.89% |
24AGL | AGILON HEALTH INC | Healthcare | $2.17B | 0.86% |
25CDNA | CAREDX INC | Healthcare | $2.05B | 0.82% |
26NUVB | NUVATION BIO INC | Healthcare | $2.03B | 0.81% |
27SNDX | SYNDAX PHARMACEUTICALS INC | Healthcare | $2.02B | 0.81% |
28PLSE | PULSE BIOSCIENCES INC | Healthcare | $1.98B | 0.79% |
29URGN | UROGEN PHARMA LTD | Healthcare | $1.96B | 0.78% |
30MRVI | MARAVAI LIFESCIENCES HOLDINGS INC | Healthcare | $1.87B | 0.75% |
31ZYME | ZYMEWORKS INC | Healthcare | $1.77B | 0.70% |
32BFLY | BUTTERFLY NETWORK INC | Healthcare | $1.73B | 0.69% |
33FTRE | FORTREA HOLDINGS INC | Healthcare | $1.68B | 0.67% |
34VIR | VIR BIOTECHNOLOGY INC | Healthcare | $1.59B | 0.63% |
35NTLA | INTELLIA THERAPEUTICS INC | Healthcare | $1.59B | 0.63% |
36PRGO | PERRIGO CO PLC | Healthcare | $1.48B | 0.59% |
37MLTX | MOONLAKE IMMUNOTHERAPEUTICS | Healthcare | $1.45B | 0.58% |
38XNCR | XENCOR INC | Healthcare | $1.30B | 0.52% |
39ABSI | ABSCI CORP | Healthcare | $1.29B | 0.52% |
40INBX | INHIBRX BIOSCIENCES INC | Healthcare | $1.28B | 0.51% |
41QDEL | QUIDELORTHO CORP | Healthcare | $1.19B | 0.47% |
42MGTX | MEIRAGTX HOLDINGS PLC | Healthcare | $1.15B | 0.46% |
43EYPT | EYEPOINT INC | Healthcare | $1.12B | 0.44% |
44CGEM | CULLINAN THERAPEUTICS INC | Healthcare | $1.09B | 0.43% |
45AVTX | AVALO THERAPEUTICS INC | Healthcare | $1.02B | 0.41% |
46VOR | VOR BIOPHARMA INC | Healthcare | $980M | 0.39% |
47KURA | KURA ONCOLOGY INC | Healthcare | $964M | 0.38% |
48ANNX | ANNEXON INC | Healthcare | $950M | 0.38% |
49REPL | REPLIMUNE GROUP INC | Healthcare | $859M | 0.34% |
50CLYM | CLIMB BIO INC | Healthcare | $727M | 0.29% |
51AURA | AURA BIOSCIENCES INC | Healthcare | $723M | 0.29% |
52CBLL | CERIBELL INC | Healthcare | $710M | 0.28% |
53SPRY | ARS PHARMACEUTICALS INC | Healthcare | $695M | 0.28% |
54EVH | EVOLENT HEALTH INC | Healthcare | $654M | 0.26% |
55TECX | TECTONIC THERAPEUTIC INC | Healthcare | $615M | 0.25% |
56NGNE | NEUROGENE INC | Healthcare | $590M | 0.24% |
57MYGN | MYRIAD GENETICS INC | Healthcare | $584M | 0.23% |
58TOI | ONCOLOGY INSTITUTE INC | Healthcare | $535M | 0.21% |
59ARVN | ARVINAS INC | Healthcare | $517M | 0.21% |
60DNA | GINKGO BIOWORKS HOLDINGS INC | Healthcare | $517M | 0.21% |
61RGNX | REGENXBIO INC | Healthcare | $511M | 0.20% |
62NVCT | NUVECTIS PHARMA INC | Healthcare | $508M | 0.20% |
63NRC | NRC HEALTH | Healthcare | $491M | 0.20% |
64SGMT | SAGIMET BIOSCIENCES INC | Healthcare | $479M | 0.19% |
65PRTA | PROTHENA CORP PUBLIC LTD CO | Healthcare | $453M | 0.18% |
66KYTX | KYVERNA THERAPEUTICS INC | Healthcare | $453M | 0.18% |
67CCRN | CROSS COUNTRY HEALTHCARE INC | Healthcare | $428M | 0.17% |
68STRO | SUTRO BIOPHARMA INC | Healthcare | $391M | 0.16% |
69UPB | UPSTREAM BIO INC | Healthcare | $382M | 0.15% |
70ZNTL | ZENTALIS PHARMACEUTICALS INC | Healthcare | $364M | 0.15% |
71VNDA | VANDA PHARMACEUTICALS INC | Healthcare | $327M | 0.13% |
72LYEL | LYELL IMMUNOPHARMA INC | Healthcare | $311M | 0.12% |
73TKNO | ALPHA TEKNOVA INC | Healthcare | $291M | 0.12% |
74MASS | 908 DEVICES INC | Healthcare | $278M | 0.11% |
75SGHT | SIGHT SCIENCES INC | Healthcare | $274M | 0.11% |
76TRDA | ENTRADA THERAPEUTICS INC | Healthcare | $268M | 0.11% |
77SRZN | SURROZEN INC | Healthcare | $255M | 0.10% |
78RNAC | CARTESIAN THERAPEUTICS INC | Healthcare | $243M | 0.10% |
79ARTV | ARTIVA BIOTHERAPEUTICS INC | Healthcare | $241M | 0.10% |
80SMTI | SANARA MEDTECH INC | Healthcare | $229M | 0.09% |
81KPTI | KARYOPHARM THERAPEUTICS INC | Healthcare | $216M | 0.09% |
82KROS | KEROS THERAPEUTICS INC | Healthcare | $211M | 0.08% |
83FOCL | FOCAL INC | Healthcare | $204M | 0.08% |
84AMWL | AMERICAN WELL CORP | Healthcare | $199M | 0.08% |
85ARCT | ARCTURUS THERAPEUTICS HOLDINGS INC | Healthcare | $172M | 0.07% |
86RCEL | AVITA MEDICAL INC | Healthcare | $157M | 0.06% |
87AARD | AARDVARK THERAPEUTICS INC | Healthcare | $128M | 0.05% |
88PIII | P3 HEALTH PARTNERS INC | Healthcare | $78M | 0.03% |
89ACET | ADICET BIO INC | Healthcare | $76M | 0.03% |
90CLNN | CLENE INC | Healthcare | $76M | 0.03% |
91SCLX | SCILEX HOLDING CO | Healthcare | $72M | 0.03% |
92EDSA | EDESA BIOTECH INC | Healthcare | $59M | 0.02% |
93MCRB | SERES THERAPEUTICS INC | Healthcare | $52M | 0.02% |
94EXOZ | EXOZYMES INC | Healthcare | $51M | 0.02% |
95TIL | INSTIL BIO INC | Healthcare | $50M | 0.02% |
Full long-leg book as of July 2026 · cap-weighted · total market cap $250.89B. Hypothetical model holdings — not a registered fund’s portfolio.
Sector Breakdown
Portfolio Style
Size × value map of the long-leg book
Share of long-leg capital by market cap × book-to-market, using terciles of the 499-name universe at July 2026. Rows: Large ≥ $3.6B, Small < $964M. Columns: Value ≥ 0.67, Growth < 0.37 B/M. The dot marks the capital-weighted centroid of the book — 82% toward Large, 59% toward Growth. +25% unclassified (26 missing size/value). Hypothetical holdings — descriptive, not realized P&L.
Capital-weighted centroid of the long leg, December 1998 → July 2026; the right-hand end is the same value as the box’s dot. 95 names now. The faded start covers early months with a much thinner universe. Hypothetical holdings — descriptive, not P&L.
Constraint checks
How this book measures against the concentration and liquidity rules — as implemented here
These are UNCONSTRAINED factor sleeves: the construction pipeline sorts on a signal and cap-weights the top bucket, applying no issuer cap, no industry cap and no liquidity screen beyond the universe filter. A failing test therefore reports a constraint that was never applied during construction — it is not a defect in the strategy and not an error in the data. The same signal can be solved subject to these constraints.
7 independent checks plus 1 arithmetically implied by another check (RIC / IRC 851(b)(3)(A) 50% bucket), which is reported separately so the tally cannot overstate scrutiny.
1 of 7 checks could not be tested. Those are neither passes nor failures — they are gaps in what the data can answer, and they are excluded from the passed count above rather than folded into it.
Engineering approximation of the cited rules for a DRAFT / HYPOTHETICAL model portfolio that is not a registered fund. This reports whether the portfolio passes the stated test AS IMPLEMENTED HERE; it is not a compliance opinion and is not a statement that any fund is compliant. Real filings need securities counsel.
No verdict sits within 1.0pp of its limit.
Data version — panel=20260719T025334 rows=2239262 asof=202607 issuers=20260719T014536 rates=20260804T224700
Measured on the 2026-07 formation date across 95 holdings (cap-weighted). A different formation date can produce different verdicts.
Derivatives risk (Rule 18f-4)
Whether this long-only book is subject to the VaR tests at all
This assessment describes the long-only book this fund holds — the top bucket only.
This fund QUALIFIES for the limited-derivatives-user exception, so it is excepted from the VaR tests; the ratio below is informational, not the operative limit.
Rule 18f-4(c)(4): a fund whose derivatives exposure (gross notional, including the value of assets sold short) is <= 10% of net assets is excepted from the VaR tests and the full derivatives risk management program.
No confidence interval: this follows from portfolio construction, not from an estimate.
Rule 18f-4(c)(2)(i): fund VaR at 99% over 20 trading days must not exceed 200% of the designated reference portfolio's VaR on the same basis.
Informational — does not governThis fund is excepted from the VaR tests, so the ratio below is context rather than the operative limit. It is shown because it is still a description of the book’s risk, not because it decides anything.
historical method · 331 monthly observations · about 3.3 in the 99% tail · paired percentile bootstrap over months
The estimators disagree about the verdict, not just the value — the choice of method decides the answer here. Historical VaR gives ratio 2.02 (fail) but Gaussian VaR gives 1.76 (pass). The pass/fail conclusion is an artefact of estimator choice, not a property of the strategy.
Engineering approximation of SEC Rule 18f-4 for research display. Not a compliance opinion and not a determination that any fund is compliant. Hypothetical model portfolio, not a registered fund.
The research long-short construction behind this factor does not qualify for this exception — a dollar-neutral book counts its full short notional, which is 100% of net assets against a 10% threshold. This product sidesteps that by holding the long leg alone, which is also why the long-leg Sharpe is reported separately throughout the site.
See the long-short verdict on the factor page →Since publication
Did the edge survive the paper coming out?
Annual return moved the other way (−3.1pp), so Sharpe and return disagree here — the change is partly a shift in volatility rather than in return.
Split at January of the year after the factor was published. The post-publication stretch IS genuinely out-of-sample relative to the original study -- the predictor was public by then -- so it speaks to whether the effect survived being known. Nothing is fitted here, so this is performance SINCE PUBLICATION, not validation of a model. Note the 'pre' side is our data before publication (our panel starts ~1999), NOT the study's original in-sample period, which usually ran decades earlier; a decay figure compares before-vs-after within our sample and is not a comparison against the published result.
Consistency across eras
Is this record broadly durable, or one regime?
3-year rolling windows, stepping 1 year (26 windows). Dispersion is the spread of window Sharpes — higher means the record depends more on which era you look at.
Rules-based factors fit no parameters, so these windows are not out-of-sample tests and do not validate a fitted model. They show whether the factor's record is consistent across eras or driven by one regime.
Returns
Long leg is what this fund holds — long-short is shown for reference
| Period | Long leg | Long-short |
|---|---|---|
| 1 yearcum. | 87.2% | 42.6% |
| 3 yearsp.a. | 29.3% | 13.5% |
| 5 yearsp.a. | 10.5% | 15.9% |
| 10 yearsp.a. | 13.2% | 7.9% |
| Since inceptionp.a. | 11.7% | 2.9% |
| Year | Long leg | Long-short |
|---|---|---|
| 20267 mo | 27.8% | 18.5% |
| 2025 | 47.1% | 25.8% |
| 2024 | 19.4% | 4.3% |
| 2023 | 2.0% | -6.6% |
| 2022 | -22.2% | 17.4% |
| 2021 | 1.7% | 37.6% |
| 2020 | 29.5% | -20.8% |
| 2019 | 26.5% | -3.3% |
| 2018 | 0.8% | 10.7% |
| 2017 | 35.6% | 14.8% |
| 2016 | -15.3% | -1.2% |
| 2015 | 11.9% | -9.5% |
| 2014 | 30.1% | -3.5% |
| 2013 | 52.6% | 8.0% |
| 2012 | 30.5% | 15.7% |
| 2011 | 6.3% | 0.9% |
| 2010 | 18.8% | 15.3% |
| 2009 | 19.1% | -12.4% |
| 2008 | -30.8% | -17.8% |
| 2007 | -0.8% | -6.9% |
| 2006 | 3.2% | 11.9% |
| 2005 | 4.0% | -3.8% |
| 2004 | -11.0% | -14.0% |
| 2003 | 57.1% | 9.9% |
| 2002 | -47.2% | -17.7% |
| 2001 | -1.6% | 4.5% |
| 2000 | 99.4% | 39.5% |
| 1999 | 33.6% | -5.9% |
Long leg = the top bucket this fund holds; long-short additionally shorts the bottom bucket and is not achievable in a long-only vehicle. Trailing figures run through July 2026: 1 year is a plain cumulative 12-month return (cum.), 3 years and longer are annualised (p.a.). Years marked with a month count are partial. These match the fact sheet’s tables by construction. Hypothetical backtest, gross of the placeholder expense ratio and trading costs — not investor results.
Fund Facts
Methodology
The Foundry Healthcare DelEqu Factor ETF tracks a rules-based model that ranks Healthcare common stocks each month by a DelEqu signal and holds the top quintile with the lowest values. Signals are computed from point-in-time Sharadar fundamentals and total-return prices. The portfolio reconstitutes monthly and is cap-weighted within the long leg.
This is a hypothetical model portfolio for research display only — not a registered fund, not an offer, and not investment advice.
Documents (draft — hypothetical)
Auto-generated from the model’s metrics and current holdings. Every document is labeled DRAFT / hypothetical.
Objective, fees, strategy, and key risks.
Full strategy, model methodology, and risks.
Policies, construction, and governance.
One-page snapshot with top holdings.
Full current constituent list.
DRAFT — HYPOTHETICAL MODEL PORTFOLIO — NOT A REGISTERED FUND, NOT AN OFFER TO SELL SECURITIES, NOT INVESTMENT ADVICE.